YL211

Phase 1Small molecule

MMediLink Therapeutics (Suzhou) Co., Ltd.

YL211 is one of 39 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

DATROWAY

Daiichi Sankyo

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 8

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 10

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 1Recruiting

Solid Tumor

NCT06384352

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1·NCT06384352·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for YL211. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YL211 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YL211. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MediLink Therapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMediLink Therapeutics (Suzhou) Co., Ltd.

YL211

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News